Entrada Therapeutics, Inc. (TRDA) Stock Forecast
TRDA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 8 analysts
- Price target
- $19.00 average of analyst targets
- Upside to target
- +334.8% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.98
- 52-week range
- $4.37 – $16.03
TRDA analyst ratings
8 analystsNumber of analysts at each rating.
TRDA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TRDA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.99 | −$1.22 | −$0.62 | −$1.06 | +6.7% | 7 |
| Current fiscal year (2026) | −$3.79 | −$4.35 | −$3.00 | −$3.47 | −9.3% | 7 |
| Next fiscal year (2027) | −$3.01 | −$4.31 | −$1.87 | −$3.79 | +20.7% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TRDA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $5.3M | $0 | $25.0M | +225.8% | 8 |
| Current fiscal year (2026) | $12.2M | $1.8M | $37.5M | −52.1% | 7 |
| Next fiscal year (2027) | $22.9M | $0 | $50.0M | +87.9% | 7 |
TRDA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TRDA revenue: reported and forecast
TRDA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.94 | −$0.98 | −$0.99 | −$0.99 | −$0.99 | +5.3% | 1 up · 1 down |
| Current fiscal year (2026) | −$3.79 | −$3.66 | −$3.79 | −$3.79 | −$3.79 | 0.0% | 1 up · 1 down |
| Next fiscal year (2027) | −$3.26 | −$3.14 | −$3.01 | −$3.01 | −$3.01 | −7.6% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TRDA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TRDA beat in 9 of 12.
What analysts expect from TRDA
8 analysts cover Entrada Therapeutics; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $19.00, 334.8% above the latest close of $4.37. Analysts expect earnings of −$3.79 per share for 2026, −9.3% from a year earlier. For 2027 the average estimate is −$3.01 per share on revenue of $22.9 million. Entrada Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: TRDA income statement, TRDA key metrics, TRDA chart. See the TRDA stock overview for the latest quote and news.
TRDA forecast FAQ
What is Entrada Therapeutics's price target?
The average analyst price target for Entrada Therapeutics is $19.00, 334.8% above the latest close of $4.37.
Is Entrada Therapeutics a buy, hold or sell?
Of 8 analysts covering Entrada Therapeutics, 7 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Entrada Therapeutics's EPS forecast?
Analysts forecast −$3.79 per share for 2026 (range −$4.35 to −$3.00); for 2027 the estimate is −$3.01.
What is Entrada Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $12.2 million, growth of −52.1%; for 2027 it is $22.9 million.
When does Entrada Therapeutics report earnings?
Entrada Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.98.
Does Entrada Therapeutics usually beat earnings estimates?
Entrada Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.